Johnson & Johnson and Crucell have entered negotiations to discuss J&J’s potential purchase of all outstanding shares of Crucell for approximately $2.3 billion in cash. J&J, through an affiliate, currently holds approximately 18% of Crucell shares and has submitted a statement to the U.S. SEC related to its change in investment intent with respect to Crucell. This potential transaction would combine Crucell’s expertise in the manufacture, discovery and commercialization of vaccine...